Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$98.98 - $115.74 $159 Million - $186 Million
1,603,046 Added 320.61%
2,103,046 $243 Million
Q2 2023

Aug 14, 2023

SELL
$96.34 - $112.38 $48.2 Million - $56.2 Million
-500,000 Reduced 50.0%
500,000 $51.4 Million
Q1 2023

May 15, 2023

SELL
$107.32 - $113.5 $53.7 Million - $56.8 Million
-500,000 Reduced 33.33%
1,000,000 $109 Million
Q4 2022

Feb 14, 2023

SELL
$62.39 - $113.8 $287 Million - $523 Million
-4,600,000 Reduced 75.41%
1,500,000 $171 Million
Q3 2022

Nov 14, 2022

SELL
$58.92 - $84.67 $5.83 Million - $8.38 Million
-99,000 Reduced 1.6%
6,100,000 $378 Million
Q2 2022

Aug 15, 2022

BUY
$79.4 - $116.36 $46.4 Million - $68.1 Million
585,000 Added 10.42%
6,199,000 $494 Million
Q1 2022

May 16, 2022

SELL
$86.42 - $109.81 $33.4 Million - $42.4 Million
-386,000 Reduced 6.43%
5,614,000 $591 Million
Q4 2021

Feb 14, 2022

SELL
$98.56 - $119.91 $16.7 Million - $20.3 Million
-169,296 Reduced 2.74%
6,000,000 $647 Million
Q3 2021

Nov 15, 2021

SELL
$91.91 - $110.37 $167 Million - $201 Million
-1,822,144 Reduced 22.8%
6,169,296 $676 Million
Q4 2020

Feb 16, 2021

BUY
$67.0 - $84.39 $87.1 Million - $110 Million
1,300,001 Added 19.43%
7,991,440 $585 Million
Q3 2020

Nov 16, 2020

SELL
$55.23 - $79.93 $11 Million - $16 Million
-200,000 Reduced 2.9%
6,691,439 $520 Million
Q2 2020

Aug 14, 2020

SELL
$30.2 - $56.98 $38.6 Million - $72.9 Million
-1,279,261 Reduced 15.66%
6,891,439 $383 Million
Q3 2019

Nov 14, 2019

BUY
$23.0 - $27.97 $34.5 Million - $42 Million
1,500,000 Added 22.49%
8,170,700 $222 Million
Q2 2019

Aug 14, 2019

BUY
$22.81 - $28.48 $152 Million - $190 Million
6,670,700 New
6,670,700 $160 Million

Others Institutions Holding HZNP

About Horizon Therapeutics Public Ltd Co


  • Ticker HZNP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 230,384,000
  • Description
  • Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...
More about HZNP
Track John Paulson's Portfolio

Track John Paulson Portfolio

Follow John Paulson (Paulson & Co. Inc.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paulson & Co. Inc., based on Form 13F filings with the SEC.

News

Stay updated on Paulson & Co. Inc. and John Paulson with notifications on news.